Navigation Links
Transgenomic, Inc. Reports Second Quarter 2007 Results
Date:8/19/2007

2006. The 2007 net loss was comprised of a loss from continuing operations of $1.0 million or $0.02 per share and a gain from discontinued operations of $66,000. The 2007 loss from continuing operations included a $0.9 million gain from the sale of an investment in equity securities and $0.6 million of restructuring charges. The 2006 net loss was comprised of a loss from continuing operations of $0.6 million or $0.01 per share and a loss from discontinued operations of $0.1 million or $0.00 per share.

Net sales from continuing operations were $11.5 million for the six months ended June 30, 2007, compared to $12.7 million during the comparable period of 2006. Gross profit from continuing operations was $6.1 million or 53 percent for the six months ended June 30, 2007 compared to $6.0 million or 48 percent in 2006. Operating expenses from continuing operations were $8.2 million for the six months ended June 30, 2007 compared to $6.7 million during the comparable period of 2006. Cash flows used in operating activities totaled $1.6 million for the six months ended June 30, 2007 compared to cash flows generated in operating activities of $0.7 million used during the same period in 2006.

Comment and Outlook

The Company's President and Chief Executive Officer, Craig Tuttle, noted, "We are very pleased with second quarter net sales. We experienced a substantial improvement over first quarter. Our instrument and consumables revenues met our internal projections and our molecular diagnostics laboratory business grew by more than $200,000 over first quarter. Second quarter net sales in our Pharmaceutical Research Services business were slightly behind our internal projections due to timing issues with receiving samples from some of our key pharmaceutical partners. We believe that we will continue to grow in our research services business and that, combined with our ongoing cost reduction efforts, will support our goal of reaching break even performance by the
'/>"/>

SOURCE Transgenomic, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... May 24 SyntheMed, Inc. (OTC Bulletin ... and commercialization of anti-adhesion products, today announced that REPEL-GYN™, ... of adhesions following gynecologic surgery, has received CE Mark ... signifies that REPEL-GYN has met the essential requirements of ...
... Mass. , May 24 Repligen Corporation (Nasdaq: ... Products Development of the Food and Drug Administration (FDA) has ... 3 (HDAC-3) inhibitor for the treatment of Friedreich,s ataxia.  Orphan ... exclusivity in the United States if the company ...
... CARLSBAD, Calif. ; May 24 MO ... microbial nucleic acid purification, announces the launch of a ... for powerful, fast and reliable homogenization and lysis of ... researchers to prepare samples for analysis faster, minimize cross-contamination, ...
Cached Biology Technology:SyntheMed Receives CE Mark Approval for REPEL-GYN™ 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 3Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 4MO BIO Laboratories, Inc. Launches PowerLyzer(TM) 24 Bench Top Bead-Based Homogenizer 2
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
(Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
(Date:4/17/2014)... BLOOMINGTON, Ind. -- Indiana University researchers have detected new ... with diabetes. This discovery could have far-reaching implications for ... the care of over 25 million Americans. , "We ... the retinas at such early stages," said Ann Elsner, ... Optometry and lead author of the study. "We set ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Energy,s Savannah River National Laboratory and the Chernobyl Center,s ... issue of the Health Physics Journal entitled, ... Zone 25 Years After the Accident," (Vol. 101, ... Office of Environmental Management,s (EM) International Program, SRNL and ...
... Energy Department,s laboratories are making headway on two projects ... charges faster, lasts longer, runs more safely, and might ... Lithium batteries are used in a variety of everyday ... battery could also significantly increase the charge capacity of ...
... named 13 U.S. Department of Energy (DOE) researchers as ... and Engineers (PECASE). This is the highest honor bestowed ... who are early in their independent research careers. The ... a variety of fields - from research to help ...
Cached Biology News:Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 2Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 3National labs leading charge on building better batteries 2US Department of Energy PECASE recipients 2US Department of Energy PECASE recipients 3US Department of Energy PECASE recipients 4
... MBPK Antibody - Red, 20X ... containing MBPK antibody at 20X concentration ... fluorescence polarization assays. ... KinEASE™ 645nm FarRed fluorescence polarization assays. ...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Biology Products: